Iterum Therapeutics PLC
NASDAQ:ITRM

Watchlist Manager
Iterum Therapeutics PLC Logo
Iterum Therapeutics PLC
NASDAQ:ITRM
Watchlist
Price: 1.81 USD 2.26% Market Closed
Market Cap: 41.1m USD
Have any thoughts about
Iterum Therapeutics PLC?
Write Note

Intrinsic Value

ITRM doesn't have a meaningful market cap.

There is not enough data to reliably calculate the intrinsic value of ITRM.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ITRM Intrinsic Value
Not Available
Base Case Scenario
How do you feel about ITRM?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Iterum Therapeutics PLC

Provide an overview of the primary business activities
of Iterum Therapeutics PLC.

What unique competitive advantages
does Iterum Therapeutics PLC hold over its rivals?

What risks and challenges
does Iterum Therapeutics PLC face in the near future?

Has there been any significant insider trading activity
in Iterum Therapeutics PLC recently?

Summarize the latest earnings call
of Iterum Therapeutics PLC.

Show all valuation multiples
for Iterum Therapeutics PLC.

Provide P/S
for Iterum Therapeutics PLC.

Provide P/E
for Iterum Therapeutics PLC.

Provide P/OCF
for Iterum Therapeutics PLC.

Provide P/FCFE
for Iterum Therapeutics PLC.

Provide P/B
for Iterum Therapeutics PLC.

Provide EV/S
for Iterum Therapeutics PLC.

Provide EV/GP
for Iterum Therapeutics PLC.

Provide EV/EBITDA
for Iterum Therapeutics PLC.

Provide EV/EBIT
for Iterum Therapeutics PLC.

Provide EV/OCF
for Iterum Therapeutics PLC.

Provide EV/FCFF
for Iterum Therapeutics PLC.

Provide EV/IC
for Iterum Therapeutics PLC.

Show me price targets
for Iterum Therapeutics PLC made by professional analysts.

What are the Revenue projections
for Iterum Therapeutics PLC?

How accurate were the past Revenue estimates
for Iterum Therapeutics PLC?

What are the Net Income projections
for Iterum Therapeutics PLC?

How accurate were the past Net Income estimates
for Iterum Therapeutics PLC?

What are the EPS projections
for Iterum Therapeutics PLC?

How accurate were the past EPS estimates
for Iterum Therapeutics PLC?

What are the EBIT projections
for Iterum Therapeutics PLC?

How accurate were the past EBIT estimates
for Iterum Therapeutics PLC?

Compare the revenue forecasts
for Iterum Therapeutics PLC with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Iterum Therapeutics PLC and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Iterum Therapeutics PLC against its competitors.

Analyze the profit margins
(gross, operating, and net) of Iterum Therapeutics PLC compared to its peers.

Compare the P/E ratios
of Iterum Therapeutics PLC against its peers.

Discuss the investment returns and shareholder value creation
comparing Iterum Therapeutics PLC with its peers.

Analyze the financial leverage
of Iterum Therapeutics PLC compared to its main competitors.

Show all profitability ratios
for Iterum Therapeutics PLC.

Provide ROE
for Iterum Therapeutics PLC.

Provide ROA
for Iterum Therapeutics PLC.

Provide ROIC
for Iterum Therapeutics PLC.

Provide ROCE
for Iterum Therapeutics PLC.

Provide Gross Margin
for Iterum Therapeutics PLC.

Provide Operating Margin
for Iterum Therapeutics PLC.

Provide Net Margin
for Iterum Therapeutics PLC.

Provide FCF Margin
for Iterum Therapeutics PLC.

Show all solvency ratios
for Iterum Therapeutics PLC.

Provide D/E Ratio
for Iterum Therapeutics PLC.

Provide D/A Ratio
for Iterum Therapeutics PLC.

Provide Interest Coverage Ratio
for Iterum Therapeutics PLC.

Provide Altman Z-Score Ratio
for Iterum Therapeutics PLC.

Provide Quick Ratio
for Iterum Therapeutics PLC.

Provide Current Ratio
for Iterum Therapeutics PLC.

Provide Cash Ratio
for Iterum Therapeutics PLC.

What is the historical Revenue growth
over the last 5 years for Iterum Therapeutics PLC?

What is the historical Net Income growth
over the last 5 years for Iterum Therapeutics PLC?

What is the current Free Cash Flow
of Iterum Therapeutics PLC?

Discuss the annual earnings per share (EPS)
trend over the past five years for Iterum Therapeutics PLC.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Iterum Therapeutics PLC

Current Assets 13.7m
Cash & Short-Term Investments 11.7m
Receivables 178k
Other Current Assets 1.8m
Non-Current Assets 479k
PP&E 416k
Other Non-Current Assets 63k
Current Liabilities 16.8m
Accounts Payable 822k
Accrued Liabilities 2.6m
Other Current Liabilities 13.3m
Non-Current Liabilities 8.3m
Long-Term Debt 8.3m
Other Non-Current Liabilities 16k
Efficiency

Earnings Waterfall
Iterum Therapeutics PLC

Revenue
0 USD
Operating Expenses
-38.3m USD
Operating Income
-38.3m USD
Other Expenses
9.9m USD
Net Income
-28.3m USD

Free Cash Flow Analysis
Iterum Therapeutics PLC

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

ITRM Profitability Score
Profitability Due Diligence

Iterum Therapeutics PLC's profitability score is 43/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Exceptional ROE
Negative Free Cash Flow
Negative Operating Income
43/100
Profitability
Score

Iterum Therapeutics PLC's profitability score is 43/100. The higher the profitability score, the more profitable the company is.

ITRM Solvency Score
Solvency Due Diligence

Iterum Therapeutics PLC's solvency score is 45/100. The higher the solvency score, the more solvent the company is.

Low D/E
Negative Net Debt
Short-Term Solvency
Long-Term Solvency
45/100
Solvency
Score

Iterum Therapeutics PLC's solvency score is 45/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ITRM Price Targets Summary
Iterum Therapeutics PLC

Wall Street analysts forecast ITRM stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ITRM is 7.65 USD with a low forecast of 5.05 USD and a high forecast of 10.5 USD.

Lowest
Price Target
5.05 USD
179% Upside
Average
Price Target
7.65 USD
323% Upside
Highest
Price Target
10.5 USD
480% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for ITRM?

Click here to dive deeper.

Dividends

Iterum Therapeutics PLC
does not pay dividends
Shareholder Yield

Current shareholder yield for ITRM is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

ITRM Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Iterum Therapeutics PLC Logo
Iterum Therapeutics PLC

Country

Ireland

Industry

Pharmaceuticals

Market Cap

41.1m USD

Dividend Yield

0%

Description

Iterum Therapeutics Plc operates as a pharmaceutical company, which engages in the development and commercialization of sulopenem to be potentially the first and only oral and intravenous (IV) branded penem available. The company is headquartered in Dublin, Dublin and currently employs 13 full-time employees. The company went IPO on 2018-05-25. The firm is focused on developing significantly differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant (MDR) pathogens. The firm is developing sulopenem - the oral and intervenous (IV) penem antibiotic demonstrating a potent spectrum of activity against multi-drug resistant gram-negative. The company is a bioavailable, antibiotic covering gram-positive, gram-negative and anaerobic pathogen with in-vitro activity against multidrug-resistant pathogens, including Extended-Spectrum Beta-Lactamase (ESBL)-producing Escherichia, coli and Klebsiella and pneumonia. The firm also developed sulopenem in an oral tablet formulation, sulopenem etzadroxil-probenecid, which is known as oral sulopenem.

Contact

DUBLIN
DUBLIN
Fitzwilliam Court, 1St Floor, Leeson Close
+35316694820.0
www.iterumtx.com

IPO

2018-05-25

Employees

13

Officers

President, CEO & Director
Mr. Corey N. Fishman
Chief Financial Officer
Ms. Judith M. Matthews
Strategic Advisor & Director
Dr. Michael W. Dunne M.D.
Senior Vice President of Technical Operations
Mr. Tom Loughman Ph.D.
Senior Vice President of Legal Affairs & Secretary
Ms. Louise Barrett
Senior VP & Head of Clinical Development
Dr. Steven I. Aronin M.D.

See Also

Discover More